

DESCRIPTION

Source *E. coli*-derived human ASP/C3a desArg protein
Ser672-Ala747
Accession # P01024

N-terminal Sequence Analysis Ser672

Predicted Molecular Mass 9 kDa

SPECIFICATIONS

SDS-PAGE 9 kDa, reducing conditions

Activity Measured by its ability to induce IL-6 secretion by LPS-stimulated human peripheral blood mononuclear cells (PBMC).
The ED₅₀ for this effect is 0.4-2.4 µg/mL.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Reconstitute at 250 µg/mL in PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

Acylation-stimulating protein (ASP), also known as C3adesArg, is an approximately 14 kDa member of the complement family that plays a role in the regulation of triglyceride synthesis (1-4). The secreted protein is a polypeptide fragment comprising amino acids (aa) 672-747 of the Complement C3 precursor protein (4). The polypeptide results from desargination of the carboxyl terminus of C3a, which is generated from interactions among C3, factor B, and adipsin (4). ASP contains a 36 aa anaphylatoxin-like domain (5). Human ASP shares 68% sequence identity with mouse and rat ASP. Increased levels of ASP are usually associated with insulin resistance, obesity and diabetes. It promotes triacylglycerol synthesis in adipocytes and inflammatory cytokine production in a septic environment (6-8).

References:

1. Cianflone, K. *et al.* (1989) J. Biol. Chem. **264**:426.
2. Baldo, A. *et al.* (1993) J. Clin. Invest. **92**:1543.
3. Havel, P. (2002) Curr. Opin. Lipidol. **13**:51.
4. Cianflone, K. *et al.* (2003) Biochim. Biophys. Acta. **1609**:127.
5. Kolev, M. *et al.* (2017) Front. Immunol. **8**:1.
6. Murray, I. *et al.* (1999) Biochem. J. **342**:41.
7. Munkonda, M. N. *et al.* (2012) PLOS One. **7**(10):1.
8. Takabayashi, T. *et al.* (1998) JID. **177**:1622.